ProMetic Sells $3.4M Worth of Synthetic Ligands to Undisclosed Customer | GenomeWeb
NEW YORK (GenomeWeb News) — ProMetic BioSciences has sold CA$3.9 million ($3.4 million) worth of its mimetic ligand affinity adsorbent product to an “existing multinational” client, the company said today.
 
ProMetic Bio, a division of ProMetic Life Sciences, said it will supply the products in the first and second quarters of 2007.
 
Earlier this month, ProMetic said it would develop synthetic ligands for Novartis' vaccine program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.